Leeds England Cancer Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.

Leeds england cancer centerOhio state universityWorld health organizationLancet oncologyPeter hillmenChronic lymphocytic leukemiaAntineoplastic drugNti cancer agentsBiologic therapyMonoclonal antibodyAdjuvant chemotherapyTyrosine kinase inhibitorAlignant neoplasiaMyelodysplastic syndrome